Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBM-007 in exudative age-related macular degeneration
NCT04200248Phase 2Completed
- Sponsor
- Ribomic Inc.
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of umedaptanib pegol in exudative age-related macular degeneration, sponsored by Ribomic Inc.. Started Dec 2019; status: completed.
02
Drugs
umedaptanib pegol
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT04200248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200248.